AstraZeneca, Teva end Pulmicort dispute

AstraZeneca Logo

Pulmicort Respules have been the subject of heated patent litigation between AstraZeneca and Teva Pharmaceuticals for quite some time, but no longer: The two companies have finally settled their dispute.

To cut the deal, Teva conceded that its generic medication infringes upon the AstraZeneca patents for Pulmicort Respules, and that AstraZeneca's patents are indeed valid and enforceable. In exchange, AstraZeneca agreed to provide an exclusive license to Teva to market and sell a generic version of the medication, beginning December 15, 2009, and agreed it will not sell its own generic version, although it will continue to market under the Pulmicort Respules brand. 

It's an expensive license apparently, for which Teva will pay "significant" (though thus far secret) royalties, which will lessen if there is competition from additional copycat products hitting the market at that time.


Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This on-demand webinar discusses the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

Perhaps in anticipation of the settlement--or perhaps convinced it could win the case--Teva shipped generic versions of the medication out last week in an "at risk" launch. If Teva had lost the case, scheduled for January, it would have had to pay AstraZeneca triple charges. However, the settlement relieved Teva of that burden, although Teva will pay AstraZeneca an undisclosed penalty sum for the launch. 

- check out Teva's release
- find the Pharmalot blog post 
- read the Wall Street Journal blog entry


Suggested Articles

Alnylam is ready to follow on its Onpattro launch with an FDA nod for Givlaari. But the drug's safety profile is giving analysts reason to pause.

FDA nominee Stephen Hahn faced questions from Senators on Wednesday on topics including drug pricing, biosimilars, opioids and more.

BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.